REMAP-CAP, ATTACC, and ACTIV-4a unified under a multi-platform randomized clinical trial with a joint Bayesian adaptive design, rapidly determining that therapeutic anticoagulation benefits moderate, but not severe, COVID-19 patients.

In this episode of "In the Interim…", Dr. Scott Berry details the design, execution, and results of the multi-platform Randomized Clinical Trial (mpRCT) pioneered during the COVID-19 pandemic.

In this episode of "In the Interim…", Dr. Scott Berry examines the analytical challenges of comparing performance across eras in both sports and clinical research.

In the 60th episode of "In the Interim…", Dr. Scott Berry, Dr. Nick Berry, and Dr. Joe Marion discuss how Berry Consultants uses AI in clinical trial design and software development.

In this episode of "In the Interim…", Dr. Scott Berry and Dr. Nick Berry investigate how futility in clinical trials and stopping rules in sports illuminate very similar decision problems, albeit with very different consequences.

ICH-E20’s regulatory caution towards adaptive designs is often misapplied, resulting in inefficient or unrealistic alternatives for sponsors and patients. Operational casework demonstrates that so-called “complexity” in adaptive design is frequently misunderstood and that regulatory “false choices” undermine trial effectiveness.